Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience

Detalhes bibliográficos
Autor(a) principal: Echeverri,Catalina Velez
Data de Publicação: 2013
Outros Autores: Valencia,Gustavo Adolfo Zuluaga, Higuita,Lina Maria Serna, Gayubo,Ana Katherina Serrano, Ochoa,Carolina Lucia, Rosas,Luisa Fernanda Rojas, Muñoz,Laura Carolina, Sierra,Javier, Zuleta,Jhon Jairo, Ruiz,Juan José Vanegas
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Nefrologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002013000300006
Resumo: INTODUCTION: Nephrotic syndrome is one of the most frequent glomerular diseases among children, and steroid therapy remains as the treatment choice. In spite of this, 10 to 15% of the patients are steroidresistant, and the best therapy for such cases has never been defined. Mycophenolate acid (MA) is one of the treatments used in such situations. OBJECTIVE: To describe the clinical behavior of children diagnosed with steroid-resistant nephrotic syndrome (SRNS) and to assess the therapeutic response to MA. METHODS: This was a retrospective and descriptive study. RESULTS: 26 clinical records of patients with SRNS; 70% male and 30% female. All patients underwent kidney biopsies, which showed a predominance of focal segmental glomerulosclerosis (FSGS). The immunosuppresive drugs used were: Mycophenolate mofetil (MMF) 100%, Cyclosporine 69.2%, Cyclophosphamide 23.1%, and Rituximab 23%. One month after treatment initiation with MMF 61.5% achieved remission. The median of relapses per year for the patients was 3 (p25: 2.75 - p75: 4). This median became 1 (p25: 1 - p75: 3.25) after using this medication (p = 0.08). Furthermore, prior to the start of the MMF treatment, the median of the steroid dose was 1 (p25: 0.5- p75: 1.62) mg/k/day. After using MMF, this median became 0.07 (p25: 0 - p75: 0.55) mg/k/day (p < 0.001), in 8 patients prednisolone was stopped. CONCLUSION: In our experience, treatment with MMF showed positive results such as decrease in the frequency of relapses, less proteinuria, and reduction in the dose of steroids administered without deterioration of glomerular filtration rates. However, more studies are needed to assess efficacy, safety, and optimal dosage.
id SBN-1_be991251c4d7eb678626c206af659648
oai_identifier_str oai:scielo:S0101-28002013000300006
network_acronym_str SBN-1
network_name_str Jornal Brasileiro de Nefrologia
repository_id_str
spelling Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experienceimmunosuppressive agentskidney failure, chronicmycophenolic acidnephrotic syndromeINTODUCTION: Nephrotic syndrome is one of the most frequent glomerular diseases among children, and steroid therapy remains as the treatment choice. In spite of this, 10 to 15% of the patients are steroidresistant, and the best therapy for such cases has never been defined. Mycophenolate acid (MA) is one of the treatments used in such situations. OBJECTIVE: To describe the clinical behavior of children diagnosed with steroid-resistant nephrotic syndrome (SRNS) and to assess the therapeutic response to MA. METHODS: This was a retrospective and descriptive study. RESULTS: 26 clinical records of patients with SRNS; 70% male and 30% female. All patients underwent kidney biopsies, which showed a predominance of focal segmental glomerulosclerosis (FSGS). The immunosuppresive drugs used were: Mycophenolate mofetil (MMF) 100%, Cyclosporine 69.2%, Cyclophosphamide 23.1%, and Rituximab 23%. One month after treatment initiation with MMF 61.5% achieved remission. The median of relapses per year for the patients was 3 (p25: 2.75 - p75: 4). This median became 1 (p25: 1 - p75: 3.25) after using this medication (p = 0.08). Furthermore, prior to the start of the MMF treatment, the median of the steroid dose was 1 (p25: 0.5- p75: 1.62) mg/k/day. After using MMF, this median became 0.07 (p25: 0 - p75: 0.55) mg/k/day (p < 0.001), in 8 patients prednisolone was stopped. CONCLUSION: In our experience, treatment with MMF showed positive results such as decrease in the frequency of relapses, less proteinuria, and reduction in the dose of steroids administered without deterioration of glomerular filtration rates. However, more studies are needed to assess efficacy, safety, and optimal dosage.Sociedade Brasileira de Nefrologia2013-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002013000300006Brazilian Journal of Nephrology v.35 n.3 2013reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.5935/0101-2800.20130032info:eu-repo/semantics/openAccessEcheverri,Catalina VelezValencia,Gustavo Adolfo ZuluagaHiguita,Lina Maria SernaGayubo,Ana Katherina SerranoOchoa,Carolina LuciaRosas,Luisa Fernanda RojasMuñoz,Laura CarolinaSierra,JavierZuleta,Jhon JairoRuiz,Juan José Vanegaseng2013-10-03T00:00:00Zoai:scielo:S0101-28002013000300006Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2013-10-03T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false
dc.title.none.fl_str_mv Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
title Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
spellingShingle Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
Echeverri,Catalina Velez
immunosuppressive agents
kidney failure, chronic
mycophenolic acid
nephrotic syndrome
title_short Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
title_full Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
title_fullStr Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
title_full_unstemmed Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
title_sort Immunosupressive therapy in children with steroid-resistant nephrotic syndrome: single center experience
author Echeverri,Catalina Velez
author_facet Echeverri,Catalina Velez
Valencia,Gustavo Adolfo Zuluaga
Higuita,Lina Maria Serna
Gayubo,Ana Katherina Serrano
Ochoa,Carolina Lucia
Rosas,Luisa Fernanda Rojas
Muñoz,Laura Carolina
Sierra,Javier
Zuleta,Jhon Jairo
Ruiz,Juan José Vanegas
author_role author
author2 Valencia,Gustavo Adolfo Zuluaga
Higuita,Lina Maria Serna
Gayubo,Ana Katherina Serrano
Ochoa,Carolina Lucia
Rosas,Luisa Fernanda Rojas
Muñoz,Laura Carolina
Sierra,Javier
Zuleta,Jhon Jairo
Ruiz,Juan José Vanegas
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Echeverri,Catalina Velez
Valencia,Gustavo Adolfo Zuluaga
Higuita,Lina Maria Serna
Gayubo,Ana Katherina Serrano
Ochoa,Carolina Lucia
Rosas,Luisa Fernanda Rojas
Muñoz,Laura Carolina
Sierra,Javier
Zuleta,Jhon Jairo
Ruiz,Juan José Vanegas
dc.subject.por.fl_str_mv immunosuppressive agents
kidney failure, chronic
mycophenolic acid
nephrotic syndrome
topic immunosuppressive agents
kidney failure, chronic
mycophenolic acid
nephrotic syndrome
description INTODUCTION: Nephrotic syndrome is one of the most frequent glomerular diseases among children, and steroid therapy remains as the treatment choice. In spite of this, 10 to 15% of the patients are steroidresistant, and the best therapy for such cases has never been defined. Mycophenolate acid (MA) is one of the treatments used in such situations. OBJECTIVE: To describe the clinical behavior of children diagnosed with steroid-resistant nephrotic syndrome (SRNS) and to assess the therapeutic response to MA. METHODS: This was a retrospective and descriptive study. RESULTS: 26 clinical records of patients with SRNS; 70% male and 30% female. All patients underwent kidney biopsies, which showed a predominance of focal segmental glomerulosclerosis (FSGS). The immunosuppresive drugs used were: Mycophenolate mofetil (MMF) 100%, Cyclosporine 69.2%, Cyclophosphamide 23.1%, and Rituximab 23%. One month after treatment initiation with MMF 61.5% achieved remission. The median of relapses per year for the patients was 3 (p25: 2.75 - p75: 4). This median became 1 (p25: 1 - p75: 3.25) after using this medication (p = 0.08). Furthermore, prior to the start of the MMF treatment, the median of the steroid dose was 1 (p25: 0.5- p75: 1.62) mg/k/day. After using MMF, this median became 0.07 (p25: 0 - p75: 0.55) mg/k/day (p < 0.001), in 8 patients prednisolone was stopped. CONCLUSION: In our experience, treatment with MMF showed positive results such as decrease in the frequency of relapses, less proteinuria, and reduction in the dose of steroids administered without deterioration of glomerular filtration rates. However, more studies are needed to assess efficacy, safety, and optimal dosage.
publishDate 2013
dc.date.none.fl_str_mv 2013-09-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002013000300006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002013000300006
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0101-2800.20130032
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
dc.source.none.fl_str_mv Brazilian Journal of Nephrology v.35 n.3 2013
reponame:Jornal Brasileiro de Nefrologia
instname:Sociedade Brasileira de Nefrologia (SBN)
instacron:SBN
instname_str Sociedade Brasileira de Nefrologia (SBN)
instacron_str SBN
institution SBN
reponame_str Jornal Brasileiro de Nefrologia
collection Jornal Brasileiro de Nefrologia
repository.name.fl_str_mv Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)
repository.mail.fl_str_mv ||jbn@sbn.org.br
_version_ 1752122063336767488